



Arstasis One Femoral Artery Access System

COMPANY	Arstasis, Inc.
PHONE	(877) 594-4545
WEB	www.arstasis.com
KEY FEATURES • A shallow-angled needle pathway provides rapid time to hemostasis • Nonocclusive pressure results in quick cessation of bleeding • Available in 5- and 6-F sheath introducers	

The US Food and Drug Administration recently granted United States marketing clearance to the Arstasis One femoral artery access system (Arstasis, Inc., San Carlos, CA). According to the company, the device allows physicians performing angiographic procedures to create a shallow-angled needle pathway through the wall of the femoral artery for placement of an introducer sheath. At the end of the procedure, when the sheath is withdrawn, the shallow-angled pathway collapses from the normal pressure of the patient's femoral artery blood flow from below and approximately 4 minutes of mild, nonocclusive pressure from above, resulting in quick cessation of bleeding and a positive experience for the clinician and patient alike. According to the company's Web site, "The resulting closed access site provides vascular closure device-like profiles in time to hemostasis and time to ambulation in diagnostic patients."



Quick-Close Vascular Closure Device

COMPANY	Interventional Therapies
PHONE	(203) 341-9100
KEY FEATURES • Vascular closure device for use in diagnostic and interventional endovascular procedures using 5- to 8-F sheaths • Ergonomic and intuitive design for improved ease of use • Reduced median time to hemostasis: 1 minute in pivotal study • Designed with no intraluminal moving parts for improved device safety • Consistent closure verified by tactile and visual feedback	

Quick-Close (Interventional Therapies, Westport, CT) is a vascular closure device that received US Food and Drug Administration pre-market approval in April 2010. The product previously received CE Mark approval in Europe. Quick-Close is approved for use in femoral arteriotomy closure in both diagnostic and interventional endovascular procedures using 5- to 8-F sheaths. According to the company, Quick-Close is designed to allow for simple, verifiable, and consistently safe vascular closure. The device enables the user to significantly reduce time to hemostasis and time to ambulation with the additional safety of verifiable suture closure.

In the pivotal trial involving 367 patients, the median time to hemostasis was 1 minute. Quick-Close has no intraluminal moving parts, thereby reducing the potential for occlusion or other device-related complications. In addition, the device has been engineered to allow the user to have a safety check at each step to ensure proper percutaneous placement and function. ■